Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India
Published: May 1, 2015 | DOI: https://doi.org/10.7860/JCDR/2015/.5895
Nithin Sashidharan, Smita Shenoy, Meena Kumari Kamal Kishore, Harish Thanusubramanian
1. Assistant Professor, Department of Pharmacology, Srinivas Institute of Medical Sciences, Mukka, Mangalore, Karnataka, India.
2. Additional Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
3. Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
4. Tutor, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka India
Correspondence
Dr. Nithin Sashidharan,
Assistant Professor, Department of Pharmacology, Srinivas Institute of Medical Sciences,
Mukka, Mangalore, Karnataka, India.
E-mail : drnithins@hotmail.com
Background: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario Aim: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma.
Settings and Design: Observational Study conducted in tertiary care centre.
Materials and Methods: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied.
Statistical Analysis: Primarily Descriptive.
Results: There was no significant difference in between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study.
Conclusion: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.
[
FULL TEXT ] | [ PDF]